Summary of Director Compensation



 EXHIBIT 10.6 
 ICAGEN, INC. 
 Summary of Director Compensation 

 Compensation of our Directors 
 Icagen, Inc. (the “Company”) reimburses non-employee directors for out-of-pocket expenses they incur in attending Board and committee meetings and pays each non-employee director an annual
retainer fee. The Chairmen of the Company’s Audit, Compensation and Nominating/Corporate Governance Committees receive an additional annual retainer. For 2008, the annual retainer fee for all non-employee directors was $25,000, and the annual
retainer for the Chairmen of the Audit, Compensation and Nominating/Corporate Governance Committee was $10,000, $3,000, and $3,000, respectively. On March 5, 2009, the Company’s Board of Directors, upon recommendation of the Compensation
Committee, approved a 50% reduction in annual retainer fees from their 2008 levels. Accordingly, the annual retainer fees for 2009 for all non-employee directors was $12,500 and the annual retainer fee for the Chairmen of the Audit, Compensation and
Nominating/Corporate Governance Committees was $5,000, $1,500 and $1,500, respectively. On December 8, 2009, the Company’s Board of Directors, upon recommendation of the Compensation Committee, approved for 2010 a 50% reduction in annual
retainer fees from their 2008 levels. Accordingly, the annual retainer fee for 2010 for all non-employee directors will continue to be $12,500, the annual retainer fee for the Chairman of the Audit, Compensation and Nominating/Corporate Governance
Committees will continue to be $5,000, $1,500 and $1,500, respectively. 
 The Company also pays each non-employee director
$1,000 for attendance at each Board meeting in which he or she participates in person or $500 if attendance is by telephone. Each non-employee director also receives $1,000 for each meeting of a committee of the Board that is held on a day other
than the day of any meeting of the full Board of Directors if he or she participates in person, or $500 if attendance is by telephone. Directors who are also the Company’s employees do not receive any compensation in their capacities as
directors. 
 Upon the commencement of service on the Board by any non-employee director, the Company grants to such person a
non-statutory stock option to purchase the number of shares of the Company’s common stock equal to the product of (i) 10,000 shares of the Company’s common stock divided by 12 and (ii) the number of full calendar months between the date of
commencement of service and the month in which the Company’s next annual meeting of stockholders is scheduled to occur. Each of the Company’s non-employee directors is also automatically granted a non-statutory stock option to purchase
10,000 shares of the Company’s common stock every year on the first business day after the Company’s Annual Meeting of Stockholders. In addition, the Company’s Chairman of the Board of Directors receives a non-statutory stock option
to purchase 20,000 additional shares of the Company’s common stock every year on the first business day after the Company’s Annual Meeting of Stockholders. All of these options are fully vested on the date of grant and have exercise prices
equal to the closing price of the Company’s common stock on the date of grant. 
 To compensate non-employee directors for
the reduction in annual retainer fees for 2009 discussed above, on March 5, 2009, the Board of Directors, upon recommendation of the Compensation Committee, granted each of the Company’s non-employee directors (other than Dennis B. Gillings,
CBE, Ph.D.), a number of restricted stock units, or RSUs, equal to (i) the dollar amount by which the annual retainer fee for 2008 was reduced, taking into account fees received by such director for service as a chairman of a committee of the Board,
divided by (ii) $0.47, the closing price of the Company’s common stock on that date. Each RSU represents the right to receive in the future one share of the Company’s common stock, subject to the terms and conditions of the applicable
restricted stock unit agreement. These RSUs vested in full on December 31, 2009. To compensate non-employee directors for the reduction in annual retainer fees for 2010 described above, on December 8, 2009, the Board of Directors, upon
recommendation of the Compensation Committee, granted each of the Company’s non-employee directors (other than Dr. Gillings) on January 4, 2010 a number of RSUs equal to (i) the dollar amount by which the annual retainer fee for 2008 was
reduced, taking into account any fees received by such director for service as a chairman of a committee of the Board, by (ii) $0.47, the closing price of the Company’s common stock on that date. Each RSU represents the right to receive in the
future one share of the Company’s common stock, subject to the terms and conditions of the applicable restricted stock unit agreement. These RSUs will vest in full on December 1, 2010. If a director ceases to serve as a member of the
Company’s Board of Directors for any reason prior to that date, all RSUs will automatically terminate and be forfeited as of the date such person ceases to serve as a member of the Board. In addition, upon the occurrence of a change of control
of Icagen, each RSU will immediately become fully vested. 







 At a meeting of the Board on March 5, 2009, Dr. Gillings voluntarily declined the RSU grant
described above as well as all retainer fees and meeting attendance fees that he would otherwise be entitled to for the remainder of 2009 as compensation for his Board service. At a meeting of the Board on June 2, 2009, Anthony B. Evnin, Ph.D.,
voluntarily declined the remaining annual retainer fees that he would otherwise be entitled to for the remainder of 2009 as compensation for his board service. Also on December 8, 2009, Dr. Gillings voluntarily declined all forms of compensation for
2010 to which he would otherwise be entitled as compensation for his board service, and Dr. Evnin voluntarily declined all forms of cash compensation for 2010 to which he would otherwise be entitled for his board service. 
 The Compensation Committee and the Board of Directors of the Company periodically reevaluate compensation of the Company’s non-employee
directors and may modify such compensation as they deem appropriate.